A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

M.D. Anderson Cancer Center

Status and phase

Completed

Phase 2

Conditions

Cutaneous T-cell Lymphoma

Chronic Lymphocytic Leukemia

Peripheral T-cell Lymphoma

Treatments

Drug: Deoxycoformycin (DCF)

Study type

Interventional

Funder types

Other

Identifiers

NCT00038025

DM94-026

Details and patient eligibility

About

The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

Full description

Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.

Enrollment

60 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.
No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.
Life expectancy of at least 12 weeks.
Performance status equal to or less than Zubrod 2.
Signed informed consent.
Patients with measurable disease.
Age at least 16 years.
Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.
Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.
Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

Exclusion criteria

No serious intercurrent illness.
Adequate contraception (if applicable).
NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.
NO experimental clinical trial within 3 weeks of study entry.
NO patients with active CNS disease.
Full recovery from any prior surgical treatment.
NO active active infections.